OncoMatch/Clinical Trials/NCT06829472

Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan

Is NCT06829472 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies melphalan for toxicities.

Phase 3RecruitingShanghai Jiao Tong University School of MedicineNCT06829472Data as of May 2026

Treatment: melphalan — Conditioning regimen with melphalan-busulfan and fludarabine (MBF) achieved low relapse rate in patients with acute myeloid leukemia (AML) and myelodysplasia syndrome (MDS). In our previous retrospective study, we demonstrated that melphalan dose at 100 or 140mg/m2 had similar incidence of relapse but it might had lower toxicities. In this prospective randomize study, we aim to compare the transplantation outcome in adult patients with AML/MDS receiving either MBF with 100 or 140 mg/m2 melphalan.

Check if I qualify

Extracted eligibility criteria

Lab requirements

Kidney function

abnormal renal function excluded

Liver function

abnormal liver function excluded

Cardiac function

abnormal cardiac function excluded

Patients with abnormal liver, renal and cardiac function [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify